Is that why TCR2 Therapeutics Inc. (Nasdaq: TCRR) shares soared in the late hours on Friday?
TCR2 Therapeutics Inc. (Nasdaq: TCRR), the stock surged higher in the after-market session as it was up 33.36% to $43.6. As a clinical-stage immunotherapy company with a pipeline of novel T cell-based therapies for cancer patients, we revealed today positive interim results from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial. In […]
